Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Extensive Stage Small Cell Lung Cancer
DRUG: Tarlatamab
Number of Participants with Dose-limiting toxicities (DLTs), Up to day 21|Number of Participants with Treatment-emergent Adverse Events (TEAEs), Up to approximately 24 months|Number of Participants with Changes in Vital Signs, Up to approximately 24 months|Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests, Up to approximately 24 months
Maximum Serum Concentration (Cmax) of Tarlatamab, Up to approximately 12 months|Serum Concentration Prior to Dosing (Ctrough) of Tarlatamab, Up to approximately 12 months|Time to Cmax (Tmax) of Tarlatamab, Up to approximately 12 months|Area Under the Concentration-time Curve (AUC) of Tarlatamab, Up to approximately 12 months|Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, Up to approximately 24 months|Duration of Response (DOR) per RECIST 1.1, Up to approximately 24 months|Time to Response (TTR) per RECIST 1.1, Up to approximately 24 months|Progression-free Survival (PFS) per RECIST 1.1, Up to approximately 24 months|Time to Progression per RECIST 1.1, Up to approximately 24 months|Time to Subsequent Therapy, Up to approximately 24 months|Overall Survival (OS), Up to approximately 24 months|Number of Participants with Anti-tarlatamab Antibody Formation, Up to approximately 24 months
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.